secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aptose Biosciences Inc. (APTOF)
CIK:        0000882361
Form:       8-K
Filed at:   2026-06-30T23:44:07+00:00
Accession:  0001193125-26-291114
Event type: m_and_a
Sentiment:  neutral
Materiality: 1.00
Item codes: 2.01, 3.03, 5.01, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aptose Biosciences acquired by Hanmi Pharmaceutical for C$2.41/share; shares to be delisted
--------------------------------------------------------------------------------

- Total consideration ~USD$3.47M for 2,043,719 shares not already owned by Hanmi.
- Premium of 28% over 30-day VWAP of C$1.88 on TSX.
- All directors resigned effective June 30, 2026.
- Common shares expected to be delisted from TSX on or about July 3, 2026.
- Company to terminate reporting obligations in US and Canada.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882361/000119312526291114/0001193125-26-291114-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882361/000119312526291114/d161768d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-291114

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer